Literature DB >> 16684884

Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome.

Richard Paylor1, Beate Glaser, Annalisa Mupo, Paris Ataliotis, Corinne Spencer, Angela Sobotka, Chelsey Sparks, Chul-Hee Choi, John Oghalai, Sarah Curran, Kieran C Murphy, Stephen Monks, Nigel Williams, Michael C O'Donovan, Michael J Owen, Peter J Scambler, Elizabeth Lindsay.   

Abstract

About 35% of patients with 22q11 deletion syndrome (22q11DS), which includes DiGeorge and velocardiofacial syndromes, develops psychiatric disorders, mainly schizophrenia and bipolar disorder. We previously reported that mice carrying a multigene deletion (Df1) that models 22q11DS have reduced prepulse inhibition (PPI), a behavioral abnormality and schizophrenia endophenotype. Impaired PPI is associated with several psychiatric disorders, including those that occur in 22q11DS, and recently, reduced PPI was reported in children with 22q11DS. Here, we have mapped PPI deficits in a panel of mouse mutants that carry deletions that partially overlap with Df1 and have defined a PPI critical region encompassing four genes. We then used single-gene mutants to identify the causative genes. We show that PPI deficits in Df1/+ mice are caused by haploinsufficiency of two genes, Tbx1 and Gnb1l. Mutation of either gene is sufficient to cause reduced PPI. Tbx1 is a transcription factor, the mutation of which is sufficient to cause most of the physical features of 22q11DS, but the gene had not been previously associated with the behavioral/psychiatric phenotype. A likely role for Tbx1 haploinsufficiency in psychiatric disease is further suggested by the identification of a family in which the phenotypic features of 22q11DS, including psychiatric disorders, segregate with an inactivating mutation of TBX1. One family member has Asperger syndrome, an autistic spectrum disorder that is associated with reduced PPI. Thus, Tbx1 and Gnb1l are strong candidates for psychiatric disease in 22q11DS patients and candidate susceptibility genes for psychiatric disease in the wider population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684884      PMCID: PMC1472513          DOI: 10.1073/pnas.0600206103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Finding nuclear localization signals.

Authors:  M Cokol; R Nair; B Rost
Journal:  EMBO Rep       Date:  2000-11       Impact factor: 8.807

2.  Isolation and characterization of a novel gene containing WD40 repeats from the region deleted in velo-cardio-facial/DiGeorge syndrome on chromosome 22q11.

Authors:  B Funke; R K Pandita; B E Morrow
Journal:  Genomics       Date:  2001-05-01       Impact factor: 5.736

3.  DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1.

Authors:  L A Jerome; V E Papaioannou
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

4.  TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome.

Authors:  S Merscher; B Funke; J A Epstein; J Heyer; A Puech; M M Lu; R J Xavier; M B Demay; R G Russell; S Factor; K Tokooya; B S Jore; M Lopez; R K Pandita; M Lia; D Carrion; H Xu; H Schorle; J B Kobler; P Scambler; A Wynshaw-Boris; A I Skoultchi; B E Morrow; R Kucherlapati
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

5.  Tbx1 haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice.

Authors:  E A Lindsay; F Vitelli; H Su; M Morishima; T Huynh; T Pramparo; V Jurecic; G Ogunrinu; H F Sutherland; P J Scambler; A Bradley; A Baldini
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

6.  Recovery from arterial growth delay reduces penetrance of cardiovascular defects in mice deleted for the DiGeorge syndrome region.

Authors:  E A Lindsay; A Baldini
Journal:  Hum Mol Genet       Date:  2001-04-15       Impact factor: 6.150

7.  Nested chromosomal deletions induced with retroviral vectors in mice.

Authors:  H Su; X Wang; A Bradley
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

Review 8.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

9.  Neuropsychiatric disorders in the 22q11 deletion syndrome.

Authors:  L Niklasson; P Rasmussen; S Oskarsdóttir; C Gillberg
Journal:  Genet Med       Date:  2001 Jan-Feb       Impact factor: 8.822

10.  Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice.

Authors:  Marta Paterlini; Stanislav S Zakharenko; Wen-Sung Lai; Jie Qin; Hui Zhang; Jun Mukai; Koen G C Westphal; Berend Olivier; David Sulzer; Paul Pavlidis; Steven A Siegelbaum; Maria Karayiorgou; Joseph A Gogos
Journal:  Nat Neurosci       Date:  2005-10-23       Impact factor: 24.884

View more
  135 in total

1.  Investigation of the 22q11.2 candidate region in patients with midline facial defects with hypertelorism.

Authors:  M Simioni; E Lopes Freitas; T Paiva Vieira; I Lopes-Cendes; V Lúcia Gil-da-Silva-Lopes
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

Review 2.  Genome-wide approaches to schizophrenia.

Authors:  Jubao Duan; Alan R Sanders; Pablo V Gejman
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 3.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

Review 4.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

Review 5.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

6.  Overt cleft palate phenotype and TBX1 genotype correlations in velo-cardio-facial/DiGeorge/22q11.2 deletion syndrome patients.

Authors:  Sean B Herman; Tingwei Guo; Donna M McDonald McGinn; Anna Blonska; Alan L Shanske; Anne S Bassett; Eva W C Chow; Mark Bowser; Molly Sheridan; Frits Beemer; Koen Devriendt; Ann Swillen; Jeroen Breckpot; M Cristina Digilio; Bruno Marino; Bruno Dallapiccola; Courtney Carpenter; Xin Zheng; Jacob Johnson; Jonathan Chung; Anne Marie Higgins; Nicole Philip; Tony Simon; Karlene Coleman; Damian Heine-Suner; Jordi Rosell; Wendy Kates; Marcella Devoto; Elaine Zackai; Tao Wang; Robert Shprintzen; Beverly S Emanuel; Bernice E Morrow
Journal:  Am J Med Genet A       Date:  2012-10-03       Impact factor: 2.802

7.  Transcription factor TBX1 overexpression induces downregulation of proteins involved in retinoic acid metabolism: a comparative proteomic analysis.

Authors:  Marianna Caterino; Margherita Ruoppolo; Gabriella Fulcoli; Tuong Huynth; Stefania Orrù; Antonio Baldini; Francesco Salvatore
Journal:  J Proteome Res       Date:  2009-03       Impact factor: 4.466

8.  Cognitive ability is associated with altered medial frontal cortical circuits in the LgDel mouse model of 22q11.2DS.

Authors:  D W Meechan; H L H Rutz; M S Fralish; T M Maynard; L A Rothblat; A-S LaMantia
Journal:  Cereb Cortex       Date:  2013-11-11       Impact factor: 5.357

Review 9.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

Review 10.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.